Epizyme

Epizyme. Epizyme was a clinical-stage biotechnology company focused on the discovery and development of novel epigenetic therapies for patients with cancer and other serious diseases. Founded in 2007 and based in Cambridge, Massachusetts, the company pioneered research into histone methyltransferases, a class of enzymes that regulate gene expression. Its lead product, tazemetostat, became the first EZH2 inhibitor approved by the U.S. Food and Drug Administration.

History

Epizyme was founded in 2007 by a consortium of scientists including Bradley Bernstein and Robert Horvitz, leveraging foundational research from institutions like Harvard University and Massachusetts General Hospital. The company secured early venture capital funding from firms such as Kleiner Perkins and Bay City Capital, enabling its initial focus on histone-modifying enzymes. In 2013, Epizyme completed an initial public offering on the NASDAQ stock exchange, raising significant capital to advance its clinical pipeline. The company operated as an independent entity until 2022, when it was acquired by the French pharmaceutical company Ipsen in a deal valued at approximately $247 million.

Technology and research

The company's scientific platform centered on targeting histone methyltransferases and histone demethylases, key enzymes within the epigenetic machinery that control chromatin structure and gene transcription. Epizyme's research extensively characterized the role of EZH2 in driving tumorigenesis across various cancers, including follicular lymphoma and malignant rhabdoid tumors. Its discovery efforts utilized high-throughput screening and structural biology techniques to identify selective small-molecule inhibitors. Beyond EZH2, the company's pipeline investigated other targets like DOT1L and MEN1, exploring their therapeutic potential in defined patient populations with specific genetic alterations.

Clinical development and products

Epizyme's lead asset, tazemetostat, received accelerated approval from the U.S. Food and Drug Administration in January 2020 for the treatment of adults and pediatric patients with advanced epithelioid sarcoma. This marked the first approval for an EZH2 inhibitor globally. Subsequently, in June 2020, the FDA granted approval for tazemetostat in patients with relapsed or refractory follicular lymphoma harboring an EZH2 mutation, as identified by a companion diagnostic. The clinical development program included pivotal trials such as the Phase 2 Study E7438-G000-101, which supported these regulatory submissions. The company also investigated tazemetostat in combination with other agents, including R-CHOP chemotherapy and pembrolizumab, for broader B-cell lymphoma indications.

Collaborations and partnerships

Epizyme established several strategic alliances to advance and commercialize its therapies. A significant early collaboration began in 2011 with Eisai Co., Ltd., granting the Japanese pharmaceutical company rights to develop and commercialize DOT1L inhibitors in Asia. In 2015, the company entered into a global license and collaboration agreement with Roche's Genentech unit for its EZH2 program, though this partnership was later restructured. Following the FDA approval of tazemetostat, Epizyme partnered with Ipsen in 2021 for exclusive commercialization rights outside the United States, an arrangement that preceded Ipsen's full acquisition. The company also engaged with the National Cancer Institute for cooperative research and development agreements.

Corporate affairs

The company was headquartered in the Kendall Square neighborhood of Cambridge, Massachusetts, a major hub for the biotechnology industry. Robert Bazemore served as President and Chief Executive Officer from 2015 until the acquisition by Ipsen. Epizyme's financial history included periods of significant research and development expenditure, funded through equity offerings, partnership milestones, and product revenue following commercialization. The acquisition by Ipsen was finalized in August 2022, integrating Epizyme's epigenetic platform and commercial operations into Ipsen's global oncology business unit, effectively concluding its run as an independent public company.